The Leader in the Treatment of Protein Misfolding Diseases

FoldRx Pharmaceuticals is a drug development company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. Since its inception in early 2004, FoldRx Pharmaceuticals has developed a portfolio of pre-clinical and clinical products to treat diseases caused by protein misfolding. The Company’s lead product, tafamidis meglumine (Fx-1006A), is being developed for TTR Amyloidosis, a fatal disease with two clinical presentations-- TTR Amyloid Polyneuropathy (ATTR-PN) and TTR Amyloid Cardiomyopathy (ATTR-CM). FoldRx recently completed a pivotal Phase II/III trial for tafamidis for ATTR-PN and is in Phase II for ATTR-CM. The company expects approval for the first indication by 2010.

http://www.foldrx.com/